Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIBSOVO vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, relapsed or refractory,Acute myeloid leukemia (AML) with an IDH2 mutation, newly diagnosed in patients ≥75 years or with comorbidities ineligible for intensive induction chemotherapy
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
500 mg orally once daily taken with or without food.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily metabolized by CYP3A4; also a minor substrate of CYP2C19, CYP2D6, and UGT1A1.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
>99.9% bound, primarily to serum albumin.
47% bound to plasma proteins (primarily albumin)
Volume of distribution (Vd/F): approximately 2.2 L/kg (range 1.7-2.8), indicating extensive extravascular distribution.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Estimated absolute bioavailability is approximately 60-70% after oral administration.
IV: 100% (only IV route); oral: not approved
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Moderate or severe hepatic impairment (Child-Pugh class B or C) has not been studied; use with caution and monitor for adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and effectiveness have not been established in pediatric patients; no dosing recommendations available.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended; clinical studies included patients aged 65 years and older, but no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
None
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Differentiation syndrome (can be fatal, treat with corticosteroids and hemodynamic support),QT prolongation (monitor ECG and electrolytes),Embryo-fetal toxicity
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
None known
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Take on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). High-fat meals significantly increase absorption; avoid concomitant intake.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposures below the clinical dose. Avoid use in pregnancy unless benefit outweighs risk. Confirm negative pregnancy test before initiation. First trimester: risk of major malformations unknown but potential. Second/third trimester: potential for fetal growth restriction and oligohydramnios due to effects on cellular metabolism. Use effective contraception during treatment and for at least 1 month after the last dose.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
No data on presence in human milk, effects on breastfed infants, or milk production. Due to potential for serious adverse reactions, breastfeedin is not recommended during treatment and for at least 1 month after the last dose. M/P ratio not available.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No formal studies in pregnancy. Dose adjustments for pregnancy-induced physiologic changes (increased plasma volume, renal clearance, hepatic metabolism) are not defined. Standard dosing (500 mg orally once daily) is used; however, close monitoring for toxicity and efficacy is warranted. Use only if clearly needed after consideration of risks.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
TIBSOVO (ivosidenib) is an IDH1 inhibitor indicated for IDH1-mutant acute myeloid leukemia (AML) and cholangiocarcinoma. Monitor for differentiation syndrome, which can be fatal; treat with corticosteroids and hemodynamic support. ECG monitoring for QTc prolongation is required; avoid concomitant use with strong CYP3A4 inhibitors or inducers. Assess liver function before and during therapy. Administer on an empty stomach at least 1 hour before or 2 hours after a meal.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Take TIBSOVO on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablets; swallow them whole.,Tell your doctor immediately if you experience fever, cough, difficulty breathing, or swelling (signs of differentiation syndrome).,Report any symptoms of heart rhythm changes (dizziness, fainting, chest pain) or liver problems (yellowing skin, dark urine, abdominal pain).,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking TIBSOVO.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIBSOVO vs CLOFARABINE, answered by our medical review team.
TIBSOVO is a Antineoplastic Agent that works by Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIBSOVO and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIBSOVO is: 500 mg orally once daily taken with or without food.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIBSOVO and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIBSOVO is classified as Category C. Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposur. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.